-
公开(公告)号：US20080305117A1
公开(公告)日：2008-12-11
申请号：US11813402
申请日：2006-01-06
申请人： Soren Berg Padkaer , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard
发明人： Soren Berg Padkaer , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard
IPC分类号： A61K39/395 , C07K16/00 , C12N5/00 , G01N33/53 , C07H21/00 , C12N15/63 , C12P21/00 , A61P37/00
CPC分类号： C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
摘要翻译： 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了用于减少KIR介导的NK细胞细胞毒性抑制的单克隆抗体的方法和试剂，而不通过例如还原或阻断KIR二聚化来降低或阻断HLA结合。
-
公开(公告)号：US20080299137A1
公开(公告)日：2008-12-04
申请号：US12091820
申请日：2006-10-27
IPC分类号： A61K39/44 , C07K16/46 , A61K31/711 , C12P21/00 , A61P35/00
CPC分类号： C07K16/2809 , A61K38/00 , A61K2039/505 , C07K2317/56 , C07K2319/00 , C07K2319/30
摘要： Novel fusion proteins that comprise a first portion that corresponds to an antibody-like protein that is specific for an activating receptor on an effector lymphocyte or a variant thereof and a second portion that corresponds to a portion of a cell membrane protein and that binds to a cell-associated target are provided, as are methods of producing such fusion proteins, uses and methods involving such fusion proteins, and compounds and compositions related to such fusion proteins.
摘要翻译： 新型融合蛋白，其包含对应于对效应淋巴细胞或其变体上的活化受体特异性的抗体样蛋白质的第一部分，以及对应于细胞膜蛋白的一部分并且与细胞膜蛋白结合的第二部分 提供了细胞相关靶，生产此类融合蛋白的方法，涉及这种融合蛋白的用途和方法，以及与这种融合蛋白相关的化合物和组合物。
-
公开(公告)号：US10253095B2
公开(公告)日：2019-04-09
申请号：US13183602
申请日：2011-07-15
IPC分类号： C07K16/28 , A61K39/395 , A61K38/20 , A61K39/00
摘要： Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
-
公开(公告)号：US09127064B2
公开(公告)日：2015-09-08
申请号：US12747095
申请日：2008-12-15
IPC分类号： C07K16/28
CPC分类号： C07K16/2851 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76 , C07K2317/92
摘要： The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21 F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.
摘要翻译： 本发明提供了可用于人类治疗应用的分离的抗人NKG2D单克隆抗体。 通常，抗体是完全人或人源化的，以最小化当施用于患者时针对抗体的免疫应答的风险。 优选的抗体包括人单克隆抗体MS和21F2。 如本文所述，其他抗原结合分子例如抗原结合抗体片段，抗体衍生物和多特异性分子可以被设计或衍生自这样的抗体。
-
5.发明授权Methods of treating viral infections by administering KIR2DL-binding antibodies 有权通过施用KIR2DL结合抗体治疗病毒感染的方法公开(公告)号：US08551483B2
公开(公告)日：2013-10-08
申请号：US11813399
申请日：2006-01-06
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/08 , C07K16/28 , C07K16/2803 , C07K16/2896 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.
摘要翻译： 描述了使用阻断抑制性NK细胞受体的化合物治疗病毒性疾病的方法，从而降低其在杀死感染的靶细胞中NK细胞的细胞毒性的抑制。 在一个实施方案中，所述化合物是结合例如人KIR2DL1，KIR2DL2和KIR2DL3受体中的一种或多种的抗体。 在另一个实施方案中，所述方法还包括施用结合感染病毒的细胞上表达的抗原的治疗性抗体或融合蛋白。
-
公开(公告)号：US20130164299A1
公开(公告)日：2013-06-27
申请号：US13807505
申请日：2011-06-28
申请人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
发明人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
IPC分类号： C07K16/18
CPC分类号： C07K16/2851 , C07K16/18 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/6872
摘要： The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
摘要翻译： 本发明涉及能够特异性结合凝集素样转录物1（LLT1）的单克隆抗体，编码这种抗体的多核苷酸和表达这种抗体的细胞。 本发明的抗体可用于治疗自身免疫疾病和癌症，其中表达LLT1和CD161的细胞在疾病发病中起作用。
-
公开(公告)号：US08614307B2
公开(公告)日：2013-12-24
申请号：US13347832
申请日：2012-01-11
申请人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurant Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkjaer , Kristian Kjaergaard , Petrus Johannes Loius Spee , Milchael Wilken
发明人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurant Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkjaer , Kristian Kjaergaard , Petrus Johannes Loius Spee , Milchael Wilken
IPC分类号： C07H21/04
CPC分类号： C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20120208237A1
公开(公告)日：2012-08-16
申请号：US13347832
申请日：2012-01-11
申请人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagné , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thórólfsson , Søren Berg Padkær , Kristian Kjaergaard , Pieter Spee , Michael Wilken
发明人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagné , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thórólfsson , Søren Berg Padkær , Kristian Kjaergaard , Pieter Spee , Michael Wilken
CPC分类号： C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20100291110A1
公开(公告)日：2010-11-18
申请号：US12813040
申请日：2010-06-10
申请人： Søren Berg Padkjaer , Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Peter Andreas Nicolai Reumert Wagtmann
发明人： Søren Berg Padkjaer , Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Peter Andreas Nicolai Reumert Wagtmann
IPC分类号： A61K39/395 , C07K16/00 , A61P37/00
CPC分类号： C07K16/2803 , C07K2317/21 , G01N33/5047
摘要： The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 本发明涉及用于调节受试者的免疫应答的新型组合物和方法。 更具体地，本发明涉及调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的特异性抗体。 本发明还涉及这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是在治疗中，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US08637258B2
公开(公告)日：2014-01-28
申请号：US12813040
申请日：2010-06-10
申请人： Soren Berg Padkjaer , Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Peter Andreas Nicolai Reumert Wagtmann
发明人： Soren Berg Padkjaer , Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Peter Andreas Nicolai Reumert Wagtmann
IPC分类号： G01N33/53 , G01N33/567 , C12P21/08 , C07K16/00
CPC分类号： C07K16/2803 , C07K2317/21 , G01N33/5047
摘要： The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.
摘要翻译： 本发明涉及产生与多个KIR2DL多肽交叉反应并中和这些多肽的抑制活性的抗体的方法。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.026 秒)
